title: Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients.
abstract: To develop a fully supervisable, monthly administered regimen for treatment of leprosy, the bactericidal effect of a single-dose combination of ofloxacin (OFLO) and minocycline (MINO), with or without rifampin (RMP), against Mycobacterium leprae was studied in the mouse footpad system and in previously untreated lepromatous leprosy patients. Bactericidal activity was measured by the proportional bactericidal method. In mouse experiments, the activity of a single dose of the combination OFLO-MINO was dosage related; the higher dosage of the combination displayed bactericidal activity which was significantly inferior to that of a single dose of RMP, whereas the lower dosage did not exhibit a bactericidal effect. In the clinical trial, 20 patients with previously untreated lepromatous leprosy were treated with a single dose consisting of either 600 mg of RMP plus 400 mg of OFLO and 100 mg of MINO or 400 mg of OFLO plus 100 mg of MINO. The OFLO-MINO combination exhibited definite bactericidal activity in 7 of 10 patients but was less bactericidal than the RMP-OFLO-MINO combination. Both combinations were well tolerated. Because of these promising results, a test of the efficacy of multiple doses of ROM in a larger clinical trial appears justified.
authors.affiliation: Faculté de Médecine Pitié-Salpêtrière, Paris, France. bacterio@biomath.jussieu.fr
authors.forename: B
authors.initials: B
authors.lastname: Ji
authors.forename: S
authors.initials: S
authors.lastname: Sow
authors.forename: E
authors.initials: E
authors.lastname: Perani
authors.forename: C
authors.initials: C
authors.lastname: Lienhardt
authors.forename: V
authors.initials: V
authors.lastname: Diderot
authors.forename: J
authors.initials: J
authors.lastname: Grosset
mesh_terms: D000293:Adolescent; D000328:Adult; D000818:Animals; D004359:Drug Therapy, Combination / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007917:Leprostatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007918:Leprosy / Q000188:drug therapy*; D008297:Male; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D008911:Minocycline / Q000008:administration & dosage / Q000009:adverse effects; D009166:Mycobacterium leprae / Q000187:drug effects*; D015242:Ofloxacin / Q000008:administration & dosage / Q000009:adverse effects; D012293:Rifampin / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D007917:Leprostatic Agents; D015242:Ofloxacin; D008911:Minocycline; D012293:Rifampin